No abstract

No abstract

No abstract

We conclude that lipid levels among north Indians are significantly higher in younger patients with CAD when compared with elderly.

No abstract

No abstract

Data analysed included demographics, disease characteristics, treatments, toxicities, response rates and survival outcomes. Inferential statistical analysis was completed using frequency table calculations, Cox proportional hazard model for univariate analysis and Kaplan Meier curves for survival data and time to event data. 3. We identified 271 pts, median age was 60 years (31-88) and divided them into 2 patient cohorts. 38% of pts (n = 103) were ≥65 years (Group 1) with a median age of 72 years (65-88) and 62% of pts (n = 168) were younger than 65 (Group 2) with a median age of 53 (31-64). There was no significant difference in progression free survival (PFS) between the two groups. 8 months (6.4-11.7) in group 1 vs 10 months (7.3-12.7) in group 2. Median OS was 29 months with group 2 exhibiting a longer OS 34 months (19.4-48.6) vs 22 months (14.7-29.3), however this was not statistically significant (p = 0.221). Among the 271 pts, 33.2% (n = 90) were diagnosed with de novo metastatic disease. 11.8% (n = 32) in group

Objective: To analyze the outcomes of patients receiving immunotherapy (IO) with advanced non-driver mutated non-small-cell lung cancer (NSCLC) after progression on systemic treatment. Methods: The overall survival (OS), progression-free survival (PFS) and best response to IO of 64 patients who met our inclusion criteria were analyzed. Results: Median follow-up, OS and PFS were 35.9, 7.1 and 3.2 months, respectively. On uni- and multi-variable analysis, better ECOG PS and fewer extra-thoracic metastases were associated with prolonged OS and PFS. Response to IO was associated with prolonged OS, while thoracic radiotherapy and isolated CNS involvement were associated with prolonged PFS. ECOG PS, thoracic radiotherapy and PDL1 status significantly influenced the likelihood of response to IO. Overall, 30% patients experienced any grade toxicity. Conclusion: Our results are concordant with reported trial outcomes and support the application of IO in Indian patients.